GlaxoSmithKline plc (ADR) (NYSE:GSK) is adding to its modest 9.1% year-to-date advance, up 0.7% at $46.63, following news the firm's malaria vaccine -- the world's first licensed human vaccine -- could be granted approval for use in Africa.
My pick of big pharma is GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US). GSK's scale gives it the R&D-spending power to be a winner in prescription drugs, whilst its vaccines and over-the-counter businesses provide stable earnings.
Pharmaceuticals and Big Oil are great sectors for the kind of long-term investment that ISAs are perfect for. It's generally better to put the tax-wrapper of an ISA around funds that you plan to leave to grow the longest.
GlaxoSmithKline plc logo GlaxoSmithKline plc (NYSE:GSK) has been given an �A+� credit rating by Morningstar. The investment research firm's �A+� rating indicates that the company is a low default risk.
GlaxoSmithKline plc (ADR) (NYSE:GSK) has been undergoing a seemingly rough patch in its US operations over the past year. In an attempt to remedy the situation, the company plans to make changes to its compensation program for its sales staff in the US ...